Brian D. Morgan
Directeur/Membre du Conseil chez Scottish Biomedical
Profil
Brian D.
Morgan is currently a Director at Scottish Biomedical, a Member at The Royal Society of Chemistry, and a Member at the Institute of Biology.
In the past, he was a Director-Supervisory Board at ProtAffin Biotechnologie AG from 2009 to 2014, a Member-Supervisory Board at 4SC AG in 2008, and a Principal at GSK Plc.
Postes actifs de Brian D. Morgan
| Sociétés | Poste | Début |
|---|---|---|
Scottish Biomedical
 Scottish Biomedical Miscellaneous Commercial ServicesCommercial Services Scottish Biomedical is a British company that specializes in biological research. The private company is based in Glasgow, UK. | Directeur/Membre du Conseil | - |
The Royal Society of Chemistry
 The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Corporate Officer/Principal | - |
| Institute of Biology | Corporate Officer/Principal | - |
Anciens postes connus de Brian D. Morgan
| Sociétés | Poste | Fin |
|---|---|---|
ProtAffin Biotechnologie AG
 ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Directeur/Membre du Conseil | 17/02/2014 |
| 4SC AG | Directeur/Membre du Conseil | 05/06/2008 |
| GSK PLC | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| 4SC AG | Health Technology |
| GSK PLC | Health Technology |
| Entreprise privées | 4 |
|---|---|
Scottish Biomedical
Scottish Biomedical Miscellaneous Commercial ServicesCommercial Services Scottish Biomedical is a British company that specializes in biological research. The private company is based in Glasgow, UK. | Commercial Services |
The Royal Society of Chemistry
The Royal Society of Chemistry Miscellaneous Commercial ServicesCommercial Services The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists. | Commercial Services |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
| Institute of Biology |
